Taken together, exogenous BMPR2 delivery is a possible therapy for PAH, but further improvements in vector technology are required to translate this approach to the clinic for the treatment of pulmonary vascular disease. This evidence concerns the gene BMPR2 and pulmonary arterial hypertension.